Alkermes PLC has reorganized its business operations to reduce spending and drive profitability, cutting 160 employees while refining its R&D priorities. The effort is expected to yield savings of $150m, the company announced on 23 October.
The restructuring could position Alkermes to improve earnings and will also mark the company's full transition from a drug delivery specialist to a drug developer
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?